These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24380126)

  • 41. Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy.
    Stroobants S; Gerlach D; Matthes F; Hartmann D; Fogh J; Gieselmann V; D'Hooge R; Matzner U
    Hum Mol Genet; 2011 Jul; 20(14):2760-9. PubMed ID: 21515587
    [TBL] [Abstract][Full Text] [Related]  

  • 42. From bedside to cell biology: a century of history on lysosomal dysfunction.
    Coutinho MF; Matos L; Alves S
    Gene; 2015 Jan; 555(1):50-8. PubMed ID: 25275857
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Perspectives from B cell immunology: fact and fancy.
    Hunt SV
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S86-99. PubMed ID: 20040318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiac involvement in Lysosomal Storage Diseases.
    Sestito S; Parisi F; Tallarico V; Tarsitano F; Roppa K; Pensabene L; Chimenz R; Ceravolo G; Calabrò MP; De Sarro R; Moricca MT; Bonapace G; Concolino D
    J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 2):107-119. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY. PubMed ID: 33000609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ten plus one challenges in diseases of the lysosomal system.
    Grabowski GA; Whitley C
    Mol Genet Metab; 2017; 120(1-2):38-46. PubMed ID: 27923545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises.
    Mohamed FE; Al-Gazali L; Al-Jasmi F; Ali BR
    Front Pharmacol; 2017; 8():448. PubMed ID: 28736525
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders.
    Pastores GM; Sathe S
    Drugs R D; 2006; 7(6):339-48. PubMed ID: 17073517
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.
    Solomon M; Muro S
    Adv Drug Deliv Rev; 2017 Sep; 118():109-134. PubMed ID: 28502768
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases.
    Hemsley KM; Hopwood JJ
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S118-23. PubMed ID: 20040322
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enzyme-replacement therapy for metabolic storage disorders.
    Brady RO; Schiffmann R
    Lancet Neurol; 2004 Dec; 3(12):752-6. PubMed ID: 15556808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hematopoietic stem cell transplant for lysosomal storage diseases.
    Lund TC
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():91-8. PubMed ID: 24380127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.
    Rohrbach M; Clarke JT
    Drugs; 2007; 67(18):2697-716. PubMed ID: 18062719
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide.
    Mehta A; Ramaswami U; Muenzer J; Giugliani R; Ullrich K; Collin-Histed T; Panahloo Z; Wellhoefer H; Frader J
    Orphanet J Rare Dis; 2021 Jan; 16(1):8. PubMed ID: 33407729
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The blood-brain barrier and neurodegenerative lysosomal storage diseases].
    Urayama A
    Brain Nerve; 2013 Feb; 65(2):153-63. PubMed ID: 23399673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Development of Enzyme Drugs Derived from Transgenic Silkworms to Treat Lysosomal Diseases].
    Itoh K; Nishioka SI; Hidaka T; Tsuji D; Maita N
    Yakugaku Zasshi; 2018; 138(7):885-893. PubMed ID: 29962464
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges.
    Köse S; Aerts-Kaya F; Uçkan Çetinkaya D; Korkusuz P
    Adv Exp Med Biol; 2021; 1347():135-162. PubMed ID: 33977438
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment for Lsds: real options for several diseases. Forward.
    Cohen IJ; Baris HN; Mistry PK; Sands MS
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():71. PubMed ID: 25345087
    [No Abstract]   [Full Text] [Related]  

  • 58. Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier.
    Critchley BJ; Gaspar HB; Benedetti S
    Mol Ther; 2023 Mar; 31(3):657-675. PubMed ID: 36457248
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities.
    Hoffmann B; Mayatepek E
    Neuropediatrics; 2005 Oct; 36(5):285-9. PubMed ID: 16217702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.